NATURE: Bishop lab helps discovery of R-loops in the pediatric cancer Embryonal tumors with multilayered rosettes (ETMRs)
December 18, 2019Frontiers in Oncology: Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
December 17, 2019The Pediatric Preclinical Testing Program previously identified the PARP inhibitor talazoparib (TLZ) as a means to potentiate temozolomide (TMZ) activity for the treatment of Ewing sarcoma. However, the combination of TLZ and TMZ has been toxic in both …
Technology News Network: Team Develop Drugs To Fight Leukemia and Lymphoma
December 9, 2019UT Health San Antonio researchers, working with collaborators at the University of Florida, have discovered a safe and potent next generation of drugs to fight multiple types of leukemia and lymphoma in adults and children. The journal Nature Medicine …
Briefings in Bioinformatics: Deep learning of pharmacogenomics resources: moving towards precision oncology
December 8, 2019Yu-Chiao Chiu, Hung-I Harry Chen, Aparna Gorthi, Milad Mostavi, Siyuan Zheng, Yufei Huang, Yidong Chen Abstract The recent accumulation of cancer genomic data provides an opportunity to understand how a tumor’s genomic characteristics can affect its re …
BioNews Central: Leukemia, lymphoma squarely in sights of new class of drugs
December 6, 2019UT Health San Antonio researchers, working with collaborators at the University of Florida, have discovered a safe and potent next generation of drugs to fight multiple types of leukemia and lymphoma in adults and children. The journal Nature Medicine …
Pediatric Blood & Cancer: Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children’s Oncology Group Phase 1 Consortium study (ADVL1411)
November 14, 2019Abstract Purpose We conducted a phase 1/2 trial of the poly(ADP‐ribose) polymerase 1/2 inhibitor talazoparib in combination with low‐dose temozolomide (TMZ) to determine the dose‐limiting toxicities (DLTs), recommended phase 2 dose (RP2D), and pharmaco …
Nicole Hensch of the Ignatius Lab Receives The Greehey Graduate Fellowship in Children’s Health
November 13, 2019Aging Cell: mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging
November 6, 2019Candice E. Van Skike, Ai‐Ling Lin, Raquel Roberts Burbank, Jonathan J. Halloran, Stephen F. Hernandez, James Cuvillier, Vanessa Y. Soto, Stacy A. Hussong, Jordan B. Jahrling, Martin A. Javors, Matthew J. Hart, Kathleen E. Fischer, Steven N. Austad, Ver …
Cell Reports: Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design
November 5, 2019Author links open overlay panelJo LynneRokita123 Komal S.Rathi23 Maria F.Cardenas4 Kristen A.Upton1 JoyJayaseelan4 Katherine L.Cross5 JacobPfeil6 Laura E.Egolf17 Gregory P.Way8 AlvinFarrel2 Nathan M.Kendsersky19 KhushbuPatel2 Krutika S.Gaon …
Neuro-Oncology Advances: PELP1 promotes glioblastoma progression by enhancing Wnt/β-catenin signaling
November 5, 2019Gangadhara R Sareddy 1 2, Uday P Pratap 1, Suryavathi Viswanadhapalli 1, Prabhakar Pitta Venkata 1, Binoj C Nair 1, Samaya Rajeshwari Krishnan 1, Siyuan Zheng 3 2, Andrea R Gilbert 4, Andrew J Brenner 5 2, Darrell W Brann 6, Ratna K Vadlamudi 1 2 Abstr …
